SHENZHEN, China, July 30,
2024 /PRNewswire/ -- Shenzhen Synthetica Pioneering
Co., Ltd. (Synthetica), a biotech startup specializing in
synthetic biology for engineering novel living bacterial
therapeutics, has recently closed a Series A funding round, led by
Boehringer Ingelheim Venture Fund and Temasek, with additional
participation from Lenovo Capital, Fosun Health Capital and
ATLATL Summer Fund. The funding will be used to fast-track
Synthetica's oncolytic bacterial pipelines into clinical
trials.
Headquartered in Shenzhen,
China, Synthetica is a biotech company founded in 2023,
specializing in genetic circuit engineering and precise control of
genes and payloads to treat various diseases. Synthetica is
currently focused on developing oncolytic bacterial therapies for
treating solid tumors. With a deep understanding of biological
mechanisms and advanced synthetic biology techniques, Synthetica is
aiming to create innovative bacterial treatments that are safe,
effective, versatile, and minimally invasive to fight cancer.
Synthetica's CEO, Yingke He stated: "Securing this funding marks
a pivotal moment for our young company as we advance the frontier
of cancer treatment. Our innovative synthetic biology approach to
developing oncolytic bacteria offers new hope for more effective
and targeted therapies. We extend our heartfelt thanks to our
technology contributors and financial investors for their trust and
support. Together we will drive this breakthrough science forward,
and make significant advancements in the fight against cancer,
bringing us closer to transforming patients' lives worldwide."
Dr. Mia Hu, Investment Director,
Boehringer Ingelheim Venture Fund, commented: "Boehringer Ingelheim
Venture Fund (BIVF) is committed to invest in innovative
therapeutics that address unmet patient needs. Oncolytic bacterial
therapy remains a key strategic focus for the Boehringer Ingelheim
Venture Fund. The Synthetica team, with its years of expertise in
quantitative synthetic biology, is pioneering the development of
innovative bacterial therapies for various indications. We are
thrilled to support Synthetica in their ongoing efforts to advance
next-generation bacterial therapies for the treatment of solid
tumors, with the ultimate goal of transforming the lives of more
people living with cancer."
About Shenzhen
Synthetica Pioneering Co., Ltd.
Shenzhen Synthetica Pioneering Co., Ltd., a spin-off from the
Shenzhen Institute of Advanced Technology (SIAT), Chinese Academy
of Sciences (CAS), is a biotech company that harnesses synthetic
biology techniques to engineer novel living bacterial therapeutics,
addressing unmet medical needs across a range of diseases. Current
lead programs focus on therapies for solid tumors.
About Boehringer Ingelheim Venture Fund
Created in 2010, the Boehringer Ingelheim Venture Fund (invests
in ground-breaking companies to drive innovation in biomedical
research. It is searching for significant enhancements in patient
care through pioneering science and its clinical translation by
building long-term relationships with scientists and entrepreneurs.
The Boehringer Ingelheim Venture Fund's focus is to target
unprecedented concepts addressing high unmet patient needs in
immuno-oncology, regenerative medicine, infectious diseases and
digital health. For more information, please visit:
www.boehringer-ingelheim-venture.com.
About Temasek
Temasek is a global investment company headquartered in
Singapore, with a net portfolio
value of S$389 billion as at
31 March 2024. Marking its unlisted
assets to market would provide S$31
billion of value uplift and bring its mark to market net portfolio
value to S$420 billion. Temasek's
Purpose "So Every Generation Prospers" guides it to make a
difference for today's and future generations. Operating on
commercial principles, Temasek seeks to deliver sustainable returns
over the long term. It has 13 offices in 9 countries around the
world: Beijing, Hanoi, Mumbai, Shanghai, Shenzhen, and Singapore in Asia; and Brussels, London, Mexico
City, New York,
Paris, San Francisco, and Washington, DC outside Asia. For more information on Temasek, please
visit www.temasek.com.sg.
About Lenovo Capital
Lenovo Capital and Incubator Group, as Lenovo's global
technology industry fund, aims to leverage Lenovo's global
resources to invest in and incubate future technology
developments.
Lenovo Capital focuses on technology industry investments, aligning
with Lenovo's "end-edge-cloud-network-intelligence" new IT
architecture, supporting Lenovo Group's service-oriented
transformation and technology-driven innovation strategy. They have
invested in over 250 portfolio companies, with 18 of them have been
successfully listed, more than 40 becoming industry leaders, and
over 100 have been rated as national and provincial level
Specialized, Refined, Differential and Innovational Enterprises.
Around 90% of the portfolios are centered around core technologies,
including artificial intelligence, semiconductor chips, smart
manufacturing, robotics, and mixed reality, among others.
About Fosun Health Capital
Shanghai Fosun Health Equity Investment Fund Management Co.,
Ltd, known as "Fosun Health Capital (FHC)," is the core CVC
investment platform initiated and established by Shanghai Fosun
Pharmaceutical (Group) Co., Ltd. (Fosun Pharma), which leverages
Fosun Pharma's 30-year accumulation in the pharmaceutical field and
its profound experience in cooperating with world-class partners.
FHC, embodying a strategic dedication to healthcare investment,
manages 11 funds with AUM over 10 billion
RMB. FHC has covered investments from early-stage ventures
to mature enterprises, spanning multiple areas including
pharmaceuticals, medical devices, and diagnostics. Fosun Health
Capital focuses on a comprehensive strategy that combines
investment and industry expertise, offering support that spans from
scientific research to operational guidance, to empower its
portfolio companies throughout their entire lifecycle and drive
their sustainable growth. FHC upholds the tenets of value
investing, becoming a discoverer, connector, and long-term
strategic partner of worldwide top-tier investment prospects.
About ATLATL Summer fund
ATLATL Summer Fund was jointly established by ATLATL Innovation
Group and Summer Capital in 2023. The fund is focused on early
innovation value discovery and consolidates the resources of both
parties, striving to achieve ecological empowerment and accelerated
incubation for the portfolio companies and innovation ecosystem.
Through the "Investment + infrastructure" model, the aim is to
build integrated value chain of innovation services based on the
infrastructure of ATLATL, supplemented by early venture capital
platform of Summer Capital, promoting the continuous acceleration
of life science innovation.
CONTACT: info@synthetica-pioneering.com
View original
content:https://www.prnewswire.com/news-releases/synthetica-pioneering-closes-a-series-a-funding-round-to-support-development-of-oncolytic-bacterial-therapy-for-solid-tumors-302209281.html
SOURCE Shenzhen Synthetica Pioneering Co., Ltd.